
IRLAB Therapeutics Q4 2022 - Still Plenty of Value

Redeye returns with a research update following the Q4 report and recent events in the company. We slightly adjust our base case and conclude that 2023 will be an important year, most notably to present the full mesdopetam data and regain investor confidence.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

IRLAB Therapeutics Q4 2022 - Still Plenty of Value